Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
Journals
JPM
Special Issues
Biomarkers and Personalized Therapy in Solid Tumors
share announcement

Biomarkers and Personalized Therapy in Solid Tumors

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Disease Biomarker".

Deadline for manuscript submissions: closed (25 September 2024) | Viewed by 9053

Special Issue Editor

Dr. Manik A. Amin

E-Mail Website
Guest Editor
Section of Hematology/Oncology, Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
Interests: gastrointestinal cancer; solid tumor; neuroendocrine neoplasm; hematological neoplasm; cancers of all types

Special Issue Information

Dear Colleagues, 

All human malignancies are primarily due to genomic alterations. It is important to identify molecular genomic alterations and their effects on core signaling pathways which describe carcinomatosis, tumor behavior, biologic tumor heterogeneity, tumor response to therapy and ultimately patient outcomes.

Along with multimodality treatment for these cancers, an emerging practice of medicine called ‘personalized medicine’ has proven an essential component of cancer treatment. Personalized medicine uses a cancer patient’s genetic profile to guide treatment decisions to maximize individual therapeutic benefits. These advancements in molecular genomic profiling provide insight into the molecular heterogeneity of different malignancies, predict clinical outcomes, help develop new therapeutic rationale for cancer treatments, and aid the discovery of new therapeutic options for patients.

In this era of personalized medicine, a wide spectrum of molecular techniques and methodologies are being developed to identify the genomic diversity of tumors, including but not limited to protein expression (via IHC) in the tissue and the proteomic analysis of the serum, plasma, peripheral blood, urine, saliva, and other body secretions to generate proteomic fingerprint information to predict outcomes in many malignancies.

This Special Issue presents cutting-edge research and clinical advancements in biomarkers in solid tumors. Original papers are especially encouraged; however, high-level systematic reviews or meta-analyses will also be considered for publication.

Dr. Manik A. Amin
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • personalized medicine
  • biomarker
  • solid tumor
  • genomic profiling
  • molecular techniques

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 1943 KiB  
Article
Fasting Blood Glucose-Based Novel Predictors in Detecting Metastases and Predicting Prognosis for Patients with PNENs
by Li Yu, Mengfei Fu, Liu Yang and Hui Sun
J. Pers. Med. 2024, 14(7), 760; https://doi.org/10.3390/jpm14070760 - 17 Jul 2024
Cited by 1 | Viewed by 1476
Abstract
Objective: To explore three novel fasting blood glucose (FBG)-based novel indicators, including the FBG-to-albumin ratio (FAR), FBG-to-lymphocytes ratio (FLR), and FBG-to-hemoglobin ratio (FHR), in predicting prognosis and detecting metastasis for patients with pancreatic neuroendocrine neoplasms (pNENs) after resection. Materials and Methods: A total [...] Read more.
Objective: To explore three novel fasting blood glucose (FBG)-based novel indicators, including the FBG-to-albumin ratio (FAR), FBG-to-lymphocytes ratio (FLR), and FBG-to-hemoglobin ratio (FHR), in predicting prognosis and detecting metastasis for patients with pancreatic neuroendocrine neoplasms (pNENs) after resection. Materials and Methods: A total of 178 pNENs patients who underwent surgical resection were included in this study. Receiver operating characteristic (ROC) curves were used to evaluate the diagnosis values of FAR, FLR, and FHR, and the cutoff values were obtained for further analyses. Univariate and multivariate analyses were conducted to determine the independent predictors. The Kaplan–Meier method was used to evaluate the progression-free survival (PFS) and overall survival (OS) of the pNENs patients. Results: The optimal cutoff values of FAR, FLR, and FHR were 0.17, 2.85, and 0.028, respectively. As for PFS, the area under the curve (AUC) was 0.693 for FAR, 0.690 for FLR, and 0.661 for FHR, respectively. The AUC was 0.770, 0.692, and 0.715 accordingly for OS. The groups with lower FAR, FLR, and FHR were significantly associated with prolonged PFS and OS (p < 0.05). In patients with metastasis, the lower FAR group was correlated with significantly longer PFS and OS (p = 0.022 and 0.002, respectively). The FLR was an independent predictor of PFS in pNENs patients, and the FAR was a predictor of OS. FAR was an independent indicator of PFS in patients with metastasis. Conclusions: Preoperative FAR, FLR, and FHR are effective in predicting the prognosis of pNEN patients and detecting the synchronous metastases. Full article
(This article belongs to the Special Issue Biomarkers and Personalized Therapy in Solid Tumors)
►▼ Show Figures

Figure 1

Review

Jump to: Research

33 pages, 1709 KiB  
Review
Evolving Management of Breast Cancer in the Era of Predictive Biomarkers and Precision Medicine
by Muhammad Zubair Afzal and Linda T. Vahdat
J. Pers. Med. 2024, 14(7), 719; https://doi.org/10.3390/jpm14070719 - 3 Jul 2024
Cited by 3 | Viewed by 3133
Abstract
Breast cancer is the most common cancer among women in the world as well as in the United States. Molecular and histological differentiation have helped clinicians optimize treatments with various therapeutics, including hormonal therapy, chemotherapy, immunotherapy, and radiation therapy. Recently, immunotherapy has become [...] Read more.
Breast cancer is the most common cancer among women in the world as well as in the United States. Molecular and histological differentiation have helped clinicians optimize treatments with various therapeutics, including hormonal therapy, chemotherapy, immunotherapy, and radiation therapy. Recently, immunotherapy has become the standard of care in locally advanced triple-negative breast cancer and an option across molecular subtypes for tumors with a high tumor mutation burden. Despite the advancements in personalized medicine directing the management of localized and advanced breast cancers, the emergence of resistance to these therapies is the leading cause of death among breast cancer patients. Therefore, there is a critical need to identify and validate predictive biomarkers to direct treatment selection, identify potential responders, and detect emerging resistance to standard therapies. Areas of active scientific and clinical research include novel personalized and predictive biomarkers incorporating tumor microenvironment, tumor immune profiling, molecular characterization, and histopathological differentiation to predict response and the potential emergence of resistance. Full article
(This article belongs to the Special Issue Biomarkers and Personalized Therapy in Solid Tumors)
►▼ Show Figures

Figure 1

31 pages, 1070 KiB  
Review
Natural Health Products for Anti-Cancer Treatment: Evidence and Controversy
by Valeria Conti, Giovanna Polcaro, Emanuela De Bellis, Danilo Donnarumma, Federica De Rosa, Berenice Stefanelli, Graziamaria Corbi, Francesco Sabbatino and Amelia Filippelli
J. Pers. Med. 2024, 14(7), 685; https://doi.org/10.3390/jpm14070685 - 26 Jun 2024
Cited by 2 | Viewed by 3891
Abstract
Natural Health Products (NHPs) have long been considered a valuable therapeutic approach for the prevention and treatment of various diseases, including cancer. However, research on this topic has led to inconclusive and often controversial results. This review aims to provide a comprehensive update [...] Read more.
Natural Health Products (NHPs) have long been considered a valuable therapeutic approach for the prevention and treatment of various diseases, including cancer. However, research on this topic has led to inconclusive and often controversial results. This review aims to provide a comprehensive update of the effects and mechanisms related to the use of NHPs, to describe the results of randomized clinical trials (RCTs) on their effects in cancer patients, and to critically discuss factors influencing clinical outcomes. RCTs available in the literature, even those studying the same NHP, are very heterogeneous in terms of indications, doses, route and timing of administration, and outcomes evaluated. Silymarin, ginsenoside, and vitamin E appear to be useful in attenuating adverse events related to radiotherapy or chemotherapy, and curcumin and lycopene might provide some benefit in patients with prostate cancer. Most RCTs have not clarified whether NHP supplementation provides any real benefit, while harmful effects have been shown in some cases. Overall, the available data suggest that although there is some evidence to support the benefits of NHPs in the management of cancer patients, further clinical trials with the same design are needed before their introduction into clinical practice can be considered. Full article
(This article belongs to the Special Issue Biomarkers and Personalized Therapy in Solid Tumors)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop